Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

I-Mab obtains Chinese IND clearance for phase I trials of TJM-2 in rheumatoid arthritis

Nov. 15, 2019

New phase II trial evaluates KN-019 in rheumatoid arthritis

Nov. 14, 2019

KINE-101, a novel synthetic peptide for rheumatoid arthritis

Nov. 14, 2019

RNA controls muscle stem cells

Nov. 13, 2019

NKTR-358 safe and well tolerated in first-in-human study

Nov. 11, 2019

Antisense therapy with antagomiR-23b shows promise for the treatment of DM1

Nov. 8, 2019

Voclosporin DDI study demonstrates no clinically significant interaction with MMF

Nov. 8, 2019

Rinvoq meets primary and all ranked secondary endpoints in phase III SELECT-PsA 2 study

Nov. 4, 2019

FDA clears IND application for phase I study of FX-201

Nov. 4, 2019

First biologic treatment approved for children with lupus in Europe

Oct. 31, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...